Neurocrine Biosciences Reports 4.7 cm Height Gain and 1.12 SDS Bone Age Reduction
NBIX•Neurocrine Biosciences’ Phase 3 CAHtalyst pediatric study showed mean bone age SDS fell by 1.12 in 24 treated children, with nine achieving over two-SD reductions and a 4.7 cm gain in predicted adult height. A caregiver survey (n=29) reported 100% satisfaction, 97% increased optimism and no new safety signals.
1. Two-Year Growth Outcomes
In the Phase 3 CAHtalyst Pediatric study, 41 growing participants were evaluated at Month 24 for bone age and predicted adult height. Among 24 patients with advanced bone age at baseline, mean bone age SDS decreased by 1.12, and nine patients achieved reductions greater than two standard deviations, leading to a 4.7 cm mean increase in predicted adult height.
2. Caregiver Satisfaction and Optimism
A cross-sectional survey of 29 caregivers reported 100% satisfaction and willingness to recommend CRENESSITY. Across respondents, 97% expressed greater hope for their child's future, 93% optimism about reducing androgen-related risks, and 79% less concern about steroid-associated weight gain.
3. Safety Profile and Steroid Reduction
Through two years of treatment, CRENESSITY was generally well tolerated, with no new safety signals observed. Sustained reductions in mean glucocorticoid dose were associated with improvements in insulin resistance, weight and BMI, suggesting potential cardiometabolic risk reduction.
